A running list, newest first. Each entry links to the original report and to the page on this site it touches. A company press release or a news story isn't a peer-reviewed result, and the entries say which they are. ## November 2026
Vertex Reports Third Quarter 2026 Financial Results
Company earnings release of November 2, 2026: it says zimislecel is designed only for patients with blood types A or A/B, and that Vertex is focusing on VX-017, an allogeneic stem cell-derived islet therapy designed to work regardless of blood type, now in a phase 1/2 trial with Fast Track designation and pivotal development expected in 2027. It gives no filing date for zimislecel and mentions no pause.
October 2026
Risk Management for Trichloroethylene (TCE)
EPA page last updated October 22, 2026: EPA issued a final TCE rule in December 2024; on October 14, 2026 it proposed moving the compliance date for several uses from December 18, 2026 to December 31, 2027, and says the TCE ban stays in place with interim workplace protections continuing. The page does not mention Parkinson's disease.
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA (pembrolizumab) at ESMO 2026 Presidential Symposium
Company press release of October 22, 2026, not a peer-reviewed paper; it says the results were accepted for publication in the New England Journal of Medicine. In the phase 3 INTerpath-001 trial of 1,137 patients with resected stage IIB to IV melanoma, adding intismeran autogene to pembrolizumab gave a recurrence-free survival hazard ratio of 0.58 (95% CI 0.45 to 0.75) at 24.6 months median follow-up, with 2-year recurrence-free survival of 82.2% versus 70.0%; overall survival was not yet mature.
FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer
On October 19, 2026 the FDA granted accelerated approval to dostarlimab (Jemperli) for adults with stage II or III locally advanced rectal cancer that is MSI-H or dMMR, based on the single-arm AZUR-1 trial of 154 treated patients, at 500 mg every three weeks for up to nine cycles. Sustained clinical complete response at 12 months was 47% by independent central review (116 evaluable patients) and 68% by investigator assessment (144 patients), with median follow-up of 26.3 months.
FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
FDA page (content current as of October 1, 2026) saying retatrutide and cagrilintide cannot be used in compounding under federal law and have not been found safe and effective for any condition, that FDA has warned companies over unapproved products falsely labeled for research purposes, and that FDA urges consumers not to buy such products, which are of unknown quality.
September 2026
FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test
Company press release reporting that the FDA's device panel voted 7 to 2 with 1 abstention that benefits outweigh risks, unanimously on safety, and 6 to 4 on effectiveness; GRAIL submitted its premarket approval application on January 29, 2026, and the FDA's decision was still pending, expected in the coming months.
Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
Company press release, not peer-reviewed. The trial of 8,323 patients with elevated Lp(a) and established cardiovascular disease did not meet its primary endpoint (cardiovascular death, nonfatal heart attack, nonfatal stroke, or urgent coronary revascularization requiring hospitalization); pelacarsen lowered Lp(a) but this did not translate into fewer cardiovascular events in the overall population (Lp(a) of 70 mg/dL or higher).
Nestle sells vitamins business to PE buyer for $1 billion
Bloomberg report (September 1, 2026) that Nestlé plans to sell its mainstream vitamins and supplements business, including Nature's Bounty, Osteo Bi-Flex, and Puritan's Pride, to the private equity firm Yellow Wood Partners for $1 billion, and that Nestlé said it remains well positioned in premium vitamins, a sector that includes brands such as Solgar and Pure Encapsulations.
August 2026
FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma
On August 26, 2026 the FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy or are not candidates for multiagent therapy, at 300 mg by mouth once daily on the label. In RASolute 302 (500 patients), median overall survival was 13.2 versus 6.7 months (hazard ratio 0.40, 95% CI 0.30 to 0.53), progression-free survival was 7.2 versus 3.6 months, and objective response was 30% versus 11%.
Eli Lilly files lawsuits against six companies for allegedly selling retatrutide
Healio news report that Lilly sued six companies it says sell counterfeit, unapproved versions of retatrutide, that retatrutide had not yet been reviewed by the FDA, that Lilly plans to submit a biologics license application in the first quarter of 2027, and that an FDA statement of June 15 said retatrutide and cagrilintide are not FDA approved for any condition and cannot be used in compounding under federal law.
The first kidney and liver tissue bioprinted in space, aboard the ISS
Trade-press report of Auxilium Biotechnologies' announcement that its AMP-1 orbital bioprinter made kidney and liver tissue, cartilage, and 28 nerve-repair implants on one flight, with cells and models from Wake Forest Institute for Regenerative Medicine; the samples returned to Earth on June 17, 2026, aboard SpaceX's CRS-34 mission.
July 2026
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
Company press release, not peer-reviewed. ZEUS enrolled over 6,300 people with atherosclerotic cardiovascular disease, chronic kidney disease, and hsCRP of 2 mg/L or higher; once-monthly ziltivekimab 15 mg lowered IL-6 and hsCRP but did not reduce major adverse cardiovascular events (HR 0.99, 95% CI 0.88 to 1.11), and serious infections were more frequent.
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (obicetrapib) and Evlarco (obicetrapib/ezetimibe)
Company press release filed July 24, 2026: the European CHMP adopted a positive opinion recommending marketing authorization for obicetrapib 10 mg alone and with ezetimibe 10 mg for primary hypercholesterolemia or mixed dyslipidemia, with a European Commission decision expected in the second half of 2026. It mentions no US filing and describes the PREVAIL outcomes trial (more than 9,500 randomized patients, enrollment completed April 2024) as ongoing.
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Company press release, not peer-reviewed: Lilly calls retatrutide an investigational once-weekly triple hormone receptor agonist and says it plans to submit a Biologics License Application to the FDA in Q1 2027. TRIUMPH-2 (1,152 people with type 2 diabetes and obesity or overweight, 80 weeks) reported weight loss of 12.7% to 20.8% versus 4.0% on placebo and A1C changes of -1.4% to -1.6% from a 7.7% baseline versus -0.2%; diarrhea ran 27.4% to 33.6% versus 13.2% on placebo and dysesthesia 4.5% to 7.3% versus 0.7%.
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
Trade-press report on Roche's AAIC 2026 presentation of PrevenTRON, a phase 3 trial that will enroll about 1,600 cognitively unimpaired adults aged 55 to 80 with elevated plasma p-tau217, with time to clinical progression as the primary endpoint. It also reports phase 1b/2a BRAINSHUTTLE AD data: at 3.6 mg/kg, amyloid fell below the 24-centiloid threshold in 91% (49/54) after 28 weeks, and ARIA-E occurred in fewer than 5% (4/149) across the 1.8 and 3.6 mg/kg cohorts.
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol
FDA announcement that Lipfendra (enlicitide), a once-daily oral tablet and the first oral PCSK9 inhibitor, approved for Merck Sharp & Dohme LLC, is an adjunct to diet and exercise to lower LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia; in two trials of 3,207 adults on maximally tolerated statins, LDL-C fell an average of 56% and 59% versus placebo at week 24, the trials' primary endpoint.
Whole-Body MRI Expands, Leaving Patients Weighing Risks
RSNA news report (July 1, 2026): whole-body MRI is expanding as a screening tool for healthy patients while radiology leaders warn that evidence of clinical benefit remains limited; of about 160 patients in Weill Cornell's first 18 months, 90% had some finding and about 1% of findings were malignant or suspected malignant, and a radiologist quoted says the data do not yet show it extends lives.
June 2026
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDA announcement dated June 15, 2026 that Tzield (teplizumab) was approved on June 12, 2026, under accelerated approval, to delay the decline of insulin production in pediatric patients aged 8 through 17 recently diagnosed with stage 3 type 1 diabetes, based on a statistically significant effect on C-peptide. It says Tzield was previously approved to delay stage 3 in people with stage 2 disease, and a required postapproval study is ongoing to verify clinical benefit.
May 2026
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
Company press release, not peer-reviewed at the time. In NHS-Galleri (142,250 participants aged 50 to 77) the test missed its primary endpoint (incidence rate ratio 1.03, 95% CI 0.92 to 1.14), while stage IV diagnoses fell 14% (incidence rate ratio 0.86); 1,801 participants had a positive result, 937 were diagnosed with cancer, positive predictive value was 52.0%, and the false positive rate was 0.45%.
Retatrutide Delivers Bariatric-Level Weight Loss in Pivotal Phase 3 TRIUMPH-1 Trial
Trade-press report of Eli Lilly's May 21, 2026 topline announcement for TRIUMPH-1: at 80 weeks weight fell 19.0%, 25.9%, and 28.3% on retatrutide 4, 9, and 12 mg, and discontinuation due to adverse events was 4.1%, 6.9%, and 11.3% versus 4.9% on placebo; it says dysesthesia occurred in a subset, was generally mild, and most affected participants continued.
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
Company press release: the phase 2b LUMA trial of the LRRK2 inhibitor BIIB122 in 648 people with early Parkinson's disease (48 to 144 weeks) did not slow progression on the combined MDS-UPDRS Part II and III score, no secondary endpoint showed a benefit, and Biogen and Denali will stop developing it for idiopathic Parkinson's, while Denali continues the phase 2a BEACON study in LRRK2 carriers with data expected in the first half of 2027.
March 2026
From 67 no's to nationwide: How Magic Mind built its functional shot business
Trade-press profile naming co-founders James Beshara and William Hicks and saying the brand has been selling since launching in March 2020.
ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia
ACC summary of the 2026 dyslipidemia guideline: LDL-C goals of under 100 mg/dL for borderline or intermediate risk, under 70 for high risk, and under 55 for very-high-risk ASCVD; ApoB may help assess residual risk once LDL-C and non-HDL-C goals are met; Lp(a) should be measured at least once in adulthood, with repeat testing generally not needed; selective coronary calcium scans for men over 40 and women over 45 at borderline or intermediate risk; PREVENT-ASCVD replaces the Pooled Cohort Equations for 10- and 30-year risk in ages 30 to 79; inclisiran is still being studied for outcomes.
Announcement on the Approval for Manufacturing and Marketing Authorization of the Allogeneic iPS Cell-Derived Dopaminergic Neural Progenitor Cell Product "AMCHEPRY" in Japan
Company announcement that Sumitomo Pharma and RACTHERA obtained conditional and time-limited approval in Japan on March 6, 2026 for AMCHEPRY (raguneprocel), an allogeneic iPS cell-derived dopaminergic neural progenitor cell product, to improve motor symptoms in people with Parkinson's disease who respond inadequately to existing drugs, with a post-marketing study and surveillance required to obtain full approval.
January 2026
Heart disease, stroke deaths down, yet still kill more in US than any other cause
News release on the 2026 AHA statistics update (2023 data): heart disease is the leading US cause of death at 22% of deaths; cardiovascular deaths were 915,973 (down from 941,652 in 2022) and coronary heart disease deaths 349,470; about 125.9 million US adults (47.3%) have high blood pressure.
October 2025
FDA Declares Nicotinamide Mononucleotide Is a Dietary Supplement
Law-firm summary of two FDA letters dated September 29, 2025 finding NMN not excluded from the dietary supplement definition under the race-to-market provision, while noting NMN remains a new dietary ingredient needing a notification (unless sourced from a supplier that already filed) and that self-affirmed GRAS cannot avoid it.
September 2025
Eli Lilly and Company - 716462 - 09/09/2025
CDER warning letter to Lilly's CEO dated 09/09/2025 about a direct-to-consumer online video of an interview featuring Lilly representatives, finding it false or misleading so that it misbrands Zepbound, and citing failure to submit it under Form FDA-2253.
August 2025
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
Company press release: in the KARDIA-3 phase 2 study (Cohort A, 270 patients) the 300 mg dose lowered office systolic pressure a placebo-adjusted 5.0 mm Hg at month 3 (p=0.0431), but the company says the study did not meet its pre-specified definition of statistical significance after multiplicity control. The companies plan the ZENITH outcomes trial of about 11,000 patients in more than 30 countries, expected to start by the end of 2025.
New High Blood Pressure Guideline Emphasizes Prevention, Early Treatment to Reduce CVD Risk
ACC release on the 2025 guideline: categories unchanged from 2017 (normal under 120/80, elevated 120 to 129, stage 1 130 to 139 or 80 to 89, stage 2 140 or higher or 90 or higher), a goal of under 130/80 mm Hg, PREVENT for 10- and 30-year risk in ages 30 to 79, urine albumin-to-creatinine ratio for everyone with high blood pressure, sodium under 2,300 mg a day, alcohol ideally none (if any, no more than 2 drinks a day for men and 1 for women), and 75 to 150 minutes a week of exercise.
June 2025
SuppCo Tested | Creatine Reality Check: The Failures We Found When Testing Popular Products
SuppCo, a supplement-rating site, reports buying 11 products (5 powders and 6 gummies) off the shelf and sending them to an unnamed ISO 17025-accredited lab. Four of the six gummies had trace or no detectable creatine, two gummies measured 6.3 g against a 5 g label serving and 4.59 g against a 4.5 g label serving, and all five powders passed with purity of 98 to 101%.